Congress Materials – Inflammatory Skin Disease Summit (ISDS 2025)
2025 Inflammatory Skin Disease Summit | Nov 12-15 | New York, NY
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Durability of Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results From APEX
Christopher T Ritchlin, Philip J Mease, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Steven Fakharzadeh*, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available on November 13th
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide, in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From the Phase 3 ICONIC-LEAD Study
Lawrence Eichenfield, Ricardo Galimberti, Adelaide Hebert, Wenhui Wang, Jennifer Soung, Nina Magnolo, John Browning, Angela Moore, Mark Lebwohl, Dagmar Wilsmann-Theis, Joseph F. Merola, Georgios Kokolakis, Dariusch Mortazawi, Parbeer Grewal, Megan Miller, Joseph Cafone, Shu Li, Gigi Jiang, Fabio Nunes, Cynthia DeKlotz, Amy Paller
This document will be available on November 13th
Guselkumab Demonstrates Effectiveness Regardless of Disease Duration: Week 76 Results from the Real-world G-EPOSS Study
Sascha Gerdes, Hjalmar Kurzen, Ulrich Neisius, Jens Ulrich, Sven Quist, Judita Makuc, Simmy Jacobsen, Nina Trenkler,* Juliane Behrens, Uwe Schwichtenberg
Guselkumab Pharmacokinetics and Immunogenicity in Pediatric Psoriasis: Phase 3 PROTOSTAR Study
Vikash Sinha, Herta Crauwels, Obinna N Obianom, Bart van Hartingsveldt, Margaret Jett, Gigi Jiang, Steve Fakharzadeh, An Vermeulen
Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b APEX Study
Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde, Joseph F Merola
This document will be available on November 13th
Pharmacokinetics of Guselkumab in Super-Responders and Long-Term Psoriasis Disease Control: Insights from the Phase 3b GUIDE Trial
Kilian Eyerich, Khusru Asadullah, Andreas Pinter, Peter Weisenseel, Carle Paul, Fabian Kreimendahl, Katharine Henry, Julian Wilke, Nenja Krüger, Nikolas Spindler, Steve Fakharzadeh, Knut Schäkel
SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement
Linda Stein Gold, Bruce Strober, April W. Armstrong, Theodore Alkousakis, Kim A. Papp, Richard Langley, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Vlada Groysman, Mark G. Lebwohl*
Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra: Subgroup Analyses of the Phase 3, ICONIC-LEAD Trial
Jennifer Soung, H. Chih-ho Hong, Benjamin Ehst, Dariusch Mortazawi, Megan Miller, Joseph Cafone, Gigi Jiang, Ya-Wen Yang, Robert Bissonnette, Mark G. Lebwohl
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
